Fulvestrant |
Faslodex |
Fulvestrant, also known as ICI 182,780, is a drug treatment of hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.[1] It is administered as a once-monthly injection. Fulvestrant is marketed by AstraZeneca with the brand name Faslodex. ...
Wikipedia - [full article]
Fulvestrant Organizations
- U.S. Food and Drug Administration http://www.fda.gov/
- Drug Digest http://www.drugdigest.org/
Resources
- Faslodex (Drug Digest)
- Faslodex Consumer Information (U.S. Food and Drug Administration)

Not Signed In -


